查看“下一代抑制剂”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>下一代抑制剂</strong>（Next-generation Inhibitor），通常指在激酶抑制剂迭代谱系中的<strong>第三代</strong>或<strong>第四代</strong>药物。它们的设计初衷非常明确：解决前一代（通常是高选择性抑制剂）治疗后出现的“在靶耐药”问题，特别是针对棘手的<strong>[[溶剂前沿突变]]</strong>（如 RET 的 [[G810]]、ALK 的 [[G1202R]]、ROS1 的 [[G2032R]]）。与前代药物相比，下一代抑制剂通常采用<strong>[[大环化]]</strong>（Macrocyclization）或极致紧凑的分子设计，以规避突变位点的<strong>[[空间位阻]]</strong>，重新恢复对激酶的结合力。此外，鉴于晚期肺癌患者高发的脑转移风险，“<strong>[[高入脑]]</strong>”（High CNS Penetration）已成为下一代抑制剂的标配属性。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Next-Gen Inhibitor</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Resistance Breaker (点击展开)</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                    [[Image:Macrocyclic_inhibitor_structure_binding_pocket.png|100px|大环结构药物结合耐药口袋示意]]
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">为克服耐药而生</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">核心使命</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">克服获得性耐药</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键靶点</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[溶剂前沿突变]]</strong><br>(Solvent Front)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">结构特征</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>[[大环分子]]</strong><br>紧凑型刚性结构</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">RET 代表</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[LOX-18228]]</strong> (EP0031)<br>HA121-28</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">ALK 代表</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[洛拉替尼]]</strong> (3代)<br>NVL-655 (4代)</td>
                </tr>
                 <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">ROS1 代表</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[瑞普替尼]]</strong><br>[[他雷替尼]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">必备能力</th>
                    <td style="padding: 6px 12px; color: #0f172a;">穿透<strong>[[血脑屏障]]</strong></td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">设计哲学：螺蛳壳里做道场</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        下一代抑制剂的研发是一场针对“空间位阻”的攻坚战。
    </p>

    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>挑战：溶剂前沿的封锁</strong>
            <br>前代药物（如赛帕替尼、克唑替尼）通常利用激酶 ATP 口袋边缘的“溶剂前沿区”来增加结合力。然而，癌细胞通过在此处引入大侧链氨基酸（如 RET 的 <strong>[[G810R]]</strong>、ALK 的 <strong>[[G1202R]]</strong>），物理上将药物“顶”出口袋，导致耐药。</li>
        <li style="margin-bottom: 12px;"><strong>对策：大环化与紧凑化</strong>
            <br>• <strong>大环化 (Macrocyclization)：</strong> 如 [[洛拉替尼]] 和 [[瑞普替尼]]。将线性分子首尾相连形成环状，限制分子的柔性，使其能以更“扁平”或更“巧妙”的姿态滑入变窄的结合口袋，避开突变位点的干扰。
            <br>• <strong>紧凑设计：</strong> 如 [[LOX-18228]]。通过优化分子体积，使其能够容纳突变后的大侧链，同时保持高亲和力。</li>
        <li style="margin-bottom: 12px;"><strong>标配：入脑能力</strong>
            <br>前代药物治疗失败的另一个常见原因是“脑转移逃逸”。下一代药物通过降低 P-糖蛋白（P-gp）的外排率，确保颅内药物浓度足以杀灭肿瘤。</li>
    </ul>

    <h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">三强争霸：各领域的破局者</h2>
    <div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;">
        <h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">不同靶点的同一条进化路</h3>
        <p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;">
            几乎所有主要致癌激酶（ALK, ROS1, RET, EGFR）的药物研发都遵循了“多靶点 -> 高选择性 -> 下一代（抗耐药）”的路径。
        </p>
    </div>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 15%;">靶点</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 30%;">前代药物 (面临耐药)</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #b91c1c; width: 25%;">最强耐药突变</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #166534; width: 30%;">下一代药物 (解决方案)</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>RET</strong></td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">[[赛帕替尼]]<br>[[普拉替尼]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[G810]]</strong> R/S/C<br>(溶剂前沿)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[LOX-18228]]</strong><br>(EP0031, A400)</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>ALK</strong></td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">[[阿来替尼]]<br>[[克唑替尼]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[G1202R]]</strong><br>(溶剂前沿)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[洛拉替尼]]</strong><br>NVL-655</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>ROS1</strong></td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">[[克唑替尼]]<br>[[恩曲替尼]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[G2032R]]</strong><br>(溶剂前沿)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[瑞普替尼]]</strong><br>[[他雷替尼]]</td>
            </tr>
        </table>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Drilon A, et al. (2021).</strong> <em>Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer.</em> <strong>[[New England Journal of Medicine]]</strong>.<br>
            <span style="color: #475569;">[大环化胜利]：证明了下一代药物（瑞普替尼）能有效克服 G2032R 这一曾经无药可解的耐药突变。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Solomon BJ, et al. (2020).</strong> <em>RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition.</em> <strong>[[Journal of Thoracic Oncology]]</strong>.<br>
            <span style="color: #475569;">[RET 领域]：明确了 RET 抑制剂的研发方向必须转向克服 G810 突变，为 LOX-18228 等药物的诞生奠定了理论基础。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [3] <strong>Shaw AT, et al. (2020).</strong> <em>Lorlatinib in advanced ROS1-positive non-small-cell lung cancer.</em> <strong>[[The Lancet Oncology]]</strong>.<br>
            <span style="color: #475569;">[CNS 突破]：展示了下一代药物在脑转移控制方面的惊人疗效，重新定义了晚期肺癌的生存预期。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            下一代抑制剂 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">进化方向</td>
                <td style="padding: 10px 15px; color: #334155;">更小(Compact) • 更圆(Macrocycle) • 更入脑(CNS)</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">主要对手</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[溶剂前沿]]</strong> (Solvent Front) 突变</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">代表药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[LOX-18228]] (RET) • [[洛拉替尼]] (ALK) • [[瑞普替尼]] (ROS1)</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">未来挑战</td>
                <td style="padding: 10px 15px; color: #334155;">复合突变 (Compound mutations) • 旁路激活</td>
            </tr>
        </table>
    </div>

</div>